Accumulating evidence suggests that primary aldosteronism (PA) is associated with several features of the metabolic syndrome, in particular with obesity, type 2 diabetes mellitus, and dyslipidemia. Whether these manifestations are primarily linked to aldosterone-producing adenoma (APA) or bilateral idiopathic hyperaldosteronism (IHA) remains unclear. The aim of the present study was to investigate differences in metabolic parameters between APA and IHA patients and to assess the impact of treatment on these clinical characteristics.
The metabolic phenotype of patients with primary aldosteronism. impact of subtype and sex - a multicenter-study of 3566 caucasian and asian subjects / Spyroglou, Ariadni; Handgriff, Laura; Müller, Lisa; Schwarzlmüller, Paul; Parasiliti-Caprino, Mirko; Fuss, Carmina Teresa; Remde, Hana; Hirsch, Anna; O'Toole, Samuel Matthew; Thuzar, Moe; Petramala, Luigi; Letizia, Claudio; Deflorenne, Elisa; Amar, Laurence; Vrckovnik, Rok; Kocjan, Tomaz; Zhang, Catherine D; Li, Dingfeng; Singh, Sumitabh; Katabami, Takuyuki; Yoneda, Takashi; Murakami, Masanori; Wada, Norio; Inagaki, Nobuya; Quinkler, Marcus; Ghigo, Ezio; Maccario, Mauro; Stowasser, Michael; Drake, William M; Fassnacht, Martin; Bancos, Irina; Reincke, Martin; Naruse, Mitsuhide; Beuschlein, Felix. - In: EUROPEAN JOURNAL OF ENDOCRINOLOGY. - ISSN 1479-683X. - 187:3(2022), pp. 361-372. [10.1530/EJE-22-0040]
The metabolic phenotype of patients with primary aldosteronism. impact of subtype and sex - a multicenter-study of 3566 caucasian and asian subjects
Petramala, Luigi;Letizia, Claudio;
2022
Abstract
Accumulating evidence suggests that primary aldosteronism (PA) is associated with several features of the metabolic syndrome, in particular with obesity, type 2 diabetes mellitus, and dyslipidemia. Whether these manifestations are primarily linked to aldosterone-producing adenoma (APA) or bilateral idiopathic hyperaldosteronism (IHA) remains unclear. The aim of the present study was to investigate differences in metabolic parameters between APA and IHA patients and to assess the impact of treatment on these clinical characteristics.| File | Dimensione | Formato | |
|---|---|---|---|
|
Spyroglou_Metabolic_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
582.78 kB
Formato
Adobe PDF
|
582.78 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
